研究单位：[1]Shanghai Pharmaceuticals Holding Co., Ltd[2]Affiliated Cancer Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510060[3]Liuzhou people's Hospital,Liuzhou,Guangxi,China,545026[4]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050011[5]Harbin Medical University cancer Hospital,Harbin,Heilongjiang,China,150081[6]Anyang Cancer Hospital,Anyang,Henan,China,455001[7]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,450052[8]Xiangyang Cancer Hospital,Wuhan,Hubei,China,441021[9]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China,210009[10]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[11]Jilin Cancer Hospital,Changchun,Jilin,China,130012[12]The First Hospital of China Medical University,Shenyang,Liaoning,China,110002[13]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750003[14]The First Affiliated Hospital of Xi'an Jiao Tong University,Xi'an,Shanxi,China,710061[15]The second people's hospital of neijiang,Neijiang,Sichuan,China,641199[16]Yunnan Cancer Hospital,Kunming,Yunnan,China,650118[17]Zhejiang cancer Hospital,Hangzhou,Zhejiang,China,310005[18]Peking Union Medical College Hospital,Beijing,China,100730
研究目的：
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.
